Oculis (NASDAQ:OCS – Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $0.25 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 12:30 PM ET.
Oculis (NASDAQ:OCS – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. The company had revenue of $0.38 million for the quarter. On average, analysts expect Oculis to post ($2.01) EPS for the current fiscal year and ($2.05) EPS for the next fiscal year.
Oculis Price Performance
Shares of OCS opened at $8.26 on Monday. The firm’s 50 day moving average price is $9.75 and its 200 day moving average price is $18.78. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a fifty-two week low of $7.11 and a fifty-two week high of $34.47. The company has a market cap of $478.91 million, a P/E ratio of -4.75 and a beta of 0.67.
Analyst Ratings Changes
OCS has been the topic of several analyst reports. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Oculis in a research report on Wednesday, October 21st. JPMorgan Chase & Co. cut their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.44.
Check Out Our Latest Research Report on Oculis
About Oculis
Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.
Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.
Read More
- Five stocks we like better than Oculis
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
